Liraglutide · source year
67 selected, source-linked Liraglutide records carrying a 2026 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
67 selected records.
4 represented types.
67 distinct public records.
Cited chronology
Literature metadata
PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata
PubMed lists PMID 42597211 in Frontiers in psychiatry as Case Reports, Journal Article, with publication-date metadata of 2026-07-30 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata
PubMed lists PMID 41970854 in ACS omega as Journal Article, with publication-date metadata of 2026-03-25 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03883412 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 38240127 at 2026-08-10T10:49:06.873Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2024-01-19. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05313529 at 2026-08-13T05:52:27.020Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 40429612 at 2026-08-10T10:49:06.946Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-05-28. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 40913889 at 2026-08-10T10:49:06.966Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-09-06. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 41321175 at 2026-08-10T10:49:07.012Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2025-12-01. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42549609 at 2026-08-10T10:49:12.984Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-04. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 38092710 at 2026-08-10T10:49:06.858Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2023-12-13. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 41651380 at 2026-08-10T10:49:08.761Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2026-02-06. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 41736232 at 2026-08-10T10:49:08.773Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-02-25. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42538646 at 2026-08-10T10:49:12.953Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42545022 at 2026-08-10T10:49:12.969Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-08-03. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42446801 at 2026-08-10T10:49:10.767Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-07-14. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 41508932 at 2026-08-10T10:49:08.740Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-01-09. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory
The Federal Register published notice 2026-15285, attributed to FDA and its parent HHS department, on 2026-07-29. Its official title is “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.
Source: Federal Register via GovInfo ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 35936066 at 2026-08-10T18:13:32.320Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2022-08-08. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07225829 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42342869 at 2026-08-10T18:13:52.311Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-06-24. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42507607 at 2026-08-10T18:13:56.762Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-07-27. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42203210 at 2026-08-10T18:13:50.682Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-05-27. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42233323 at 2026-08-10T18:13:50.725Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-03. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42286095 at 2026-08-10T18:13:52.266Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-12. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42356253 at 2026-08-10T18:13:53.759Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42394413 at 2026-08-10T18:13:53.810Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-03. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42500463 at 2026-08-10T18:13:56.748Z. PubMed recorded a metadata revision date of 2026-07-25 and an Entrez history date of 2026-07-25. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 40521838 at 2026-08-10T18:13:37.865Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2025-06-16. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42491030 at 2026-08-10T18:13:56.726Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 41160027 at 2026-08-10T18:13:37.970Z. PubMed recorded a metadata revision date of 2026-07-21 and an Entrez history date of 2025-10-29. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42392029 at 2026-08-10T18:13:53.799Z. PubMed recorded a metadata revision date of 2026-07-21 and an Entrez history date of 2026-07-02. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42470452 at 2026-08-10T18:13:56.686Z. PubMed recorded a metadata revision date of 2026-07-18 and an Entrez history date of 2026-07-18. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PubMed lists PMID 41966799 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2026-04-10 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata
PubMed lists PMID 42442575 in International journal of biological macromolecules as Journal Article, with publication-date metadata of 2026-07-13 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory
DailyMed lists Structured Product Labeling version 6 for the reviewed Liraglutide label family with a published date of 2026-07-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Literature metadata
PubMed lists PMID 30515941 in Journal of clinical hypertension (Greenwich, Conn.) as Letter, with publication-date metadata of 2018-12-05 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata
PubMed lists PMID 37967247 in The Journal of clinical endocrinology and metabolism as Randomized Controlled Trial, Journal Article, with publication-date metadata of 2024-04-19 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 212972 with status AP dated 2026-07-01, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Literature metadata
PubMed lists PMID 41604908 in Biomaterials advances as Journal Article, with publication-date metadata of 2026-01-14 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42385677 at 2026-07-30T16:11:44.943Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-07-01. PeptideScanner associated this retained record with the identity slug liraglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PubMed lists PMID 39949066 in Annals of clinical and translational neurology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-02-13 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata
PubMed lists PMID 42015323 in Journal of pharmaceutical health care and sciences as Journal Article, with publication-date metadata of 2026-04-21 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory
The Federal Register published notice 2026-12937, attributed to FDA and its parent HHS department, on 2026-06-26. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide, Semaglutide and Tirzepatide.
Source: Federal Register via GovInfo ↗
Literature metadata
PubMed lists PMID 38757729 in Diabetes, obesity & metabolism as Journal Article, Clinical Trial, with publication-date metadata of 2024-05-17 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 213155 with status AP dated 2026-06-15, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Literature metadata
PubMed lists PMID 40646278 in Journal of neural transmission (Vienna, Austria : 1996) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-07-12 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata
PubMed lists PMID 40914786 in Drug delivery and translational research as Journal Article, Review, with publication-date metadata of 2025-09-06 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Safety
FDA's dated enforcement report D-0541-2026 lists Class II and source status Ongoing for Lupin Pharmaceuticals Inc. PeptideScanner connects the report to reviewed application ANDA215421 through exact openFDA application-number annotations.
Literature metadata
PubMed lists PMID 38619705 in Drug delivery and translational research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-04-15 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata
PubMed lists PMID 31034184 in The New England journal of medicine as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-04-28 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04575844 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Regulatory
The Federal Register published notice 2026-08552, attributed to FDA and its parent HHS department, on 2026-05-01. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide and Tirzepatide.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02944500 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03856632 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-01, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Regulatory
FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use for compounding.
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 212552 with status AP dated 2026-03-30, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 215245 with status AP dated 2026-03-11, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05965908 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-06, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05681299 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-04, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Regulatory
DailyMed lists Structured Product Labeling version 3 for the reviewed Liraglutide label family with a published date of 2026-02-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 217063 with status AP dated 2026-02-24, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 217234 with status AP dated 2026-02-24, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 217590 with status AP dated 2026-01-14, and names liraglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Safety
FDA asked manufacturers to remove suicidal behavior and ideation warning language from certain semaglutide, tirzepatide, and liraglutide labels.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06283641 at 2026-07-30T16:25:18.013Z. Its registry update date was 2026-01-09, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗